共 50 条
- [41] EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohortsANNALS OF ONCOLOGY, 2022, 33 : S298 - S298Muro, K.Bruce, J. YangBaranda, J.Campbell, M.Wu, C.Gorla, S.Braiteh, F.
- [42] Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled TrialJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 93 - 105Zhou, CaicunHuang, DingzhiFan, YunYu, XinminLiu, YunpengShu, YongqianMa, ZhiyongWang, ZipingCheng, YingWang, JieHu, ShengLiu, ZhihuaPoddubskaya, ElenaDisel, UmutAkopov, AndreyDvorkin, MikhailZheng, WenjuanMa, YiyuanWang, YanLi, SongziYu, CunjingRivalland, Gareth
- [43] An open-label, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or with Standard Chemotherapy versus Standard Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO First-line Therapy for untreated, non-resectable or metastatic Urothelial CarcinomaUROLOGE, 2018, 57 (07): : 880 - 881Rexer, H.Retz, M.Waller, C.
- [44] Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progressANNALS OF ONCOLOGY, 2022, 33 : S352 - S352Sun, J.Enzinger, P.Adenis, A.Shah, M.Kato, K.Bennouna, J.Doi, T.Hawk, N.Yu, L.Shah, S.Bhagia, P.Shen, L.
- [46] Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patientsCANCER, 2022, 128 (05) : 995 - 1003Chung, Hyun CheolKang, Yoon-KooChen, ZhendongBai, YuxianIshak, Wan Zamaniah WanShim, Byoung YongPark, Young LeeKoo, Dong-HoeLu, JianweiXu, JianmingChon, Hong JaeBai, Li-YuanZeng, ShanYuan, YingChen, Yen-YangGu, KangshengZhong, Wen YanKuang, ShuShih, Chie-SchinQin, Shu-Kui
- [47] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialLANCET, 2019, 393 (10183): : 1819 - 1830Mok, Tony S. K.Wu, Yi-LongKudaba, IvetaKowalski, Dariusz M.Cho, Byoung ChulTurna, Hande Z.Castro, Gilberto, Jr.Srimuninnimit, VichienLaktionov, Konstantin K.Bondarenko, IgorKubota, KaoruLubiniecki, Gregory M.Zhang, JinKush, DebraLopes, Gilberto
- [48] Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Dreyling, martin H.Tam, Constantine Si LunWang, MichaelSmith, Stephen DouglasLadetto, MarcoHuang, HuiqiangElstrom, Rebecca L.Co, MelannieHolmgren, EricHuang, JaneGouill, Steven Le
- [49] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)Galsky, Matt D.Powles, ThomasLi, ShengtingHennicken, DelphineSonpavde, Guru
- [50] Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial (vol 21, pg 1574, 2020)LANCET ONCOLOGY, 2021, 22 (01): : E5 - E5Powles, T.van der Heijden, M. S.Castellano, D.